Arecor Therapeutics (LON:AREC) Stock Price Breaks Above Fifty Day Moving Average – What’s Next?

Arecor Therapeutics plc (LON:AREC – Get Free Report)’s share price crossed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of GBX 80.58 and traded as high as GBX 81.50. Arecor Therapeutics shares last traded at GBX 81.50, with a volume of 2,750 shares.

Arecor Therapeutics Price Performance

The company’s 50-day simple moving average is GBX 80.58 and its 200 day simple moving average is GBX 70.98. The company has a market cap of £33.98 million, a PE ratio of 75.00 and a beta of -0.18. The company has a debt-to-equity ratio of 1.55, a quick ratio of 6.24 and a current ratio of 4.29.

Arecor Therapeutics (LON:AREC – Get Free Report) last posted its quarterly earnings data on Thursday, October 1st. The company reported GBX (8) earnings per share for the quarter. Arecor Therapeutics had a positive return on equity of 3.75% and a negative net margin of 200.00%. On average, sell-side analysts predict that Arecor Therapeutics plc will post -0.35 earnings per share for the current fiscal year.

Arecor Therapeutics Company Profile

(Get Free Report)

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases. Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.

Featured Stories

• Five stocks we like better than Arecor Therapeutics
• Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
• Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
• Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
• A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions

Receive News & Ratings for Arecor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arecor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.